Fundraising Fox
Odyssey Therapeutics
Cambridge, US · Founded 2021 · Delaware corporation · 126 employees on LinkedIn · 19 known investors
Find your way into Odyssey Therapeutics
Sign up to see every warm intro you have to Odyssey Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Odyssey Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation. Its pipeline focuses on autoimmune and inflammatory diseases with large patient populations and unmet medical need.
Founders & leadership
Odyssey Therapeutics was founded in 2021 by Gary D Glick.
Board
Investors · 19
How we know: Ascenta Capital's portfolio page · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Catalio Capital Management, LP's portfolio page · Not right? Tell us
How we know: Foresite Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Global BioAccess Fund's portfolio page · Not right? Tell us
How we know: GreatPoint Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: Jeito Capital's portfolio page · board seat on SEC Form D · odysseytx.com · Not right? Tell us
How we know: Lightspeed Venture Partners's portfolio page · odysseytx.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: OrbiMed's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: Sanofi Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: SR One Capital Management's portfolio page · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: board seat on SEC Form D · odysseytx.com · the VCSheet dataset · Not right? Tell us
.png)
Also in the syndicate · 3
Funding
SEC filings, press & company announcements$894.9M disclosed across 5 rounds · 2021–2026
- $304MIPOMay 2026Source ↗
▶$214MraisedDec 2025 · 55 investors · BiotechnologyRule 506(b)
- Valerie OdegardDirector
- Carl GordonDirector
- Carolyn NgDirector
- Gary D. GlickExecutive Officer, Director
- Timothy WalbertDirector
- Paulina HillDirector
- Nan LiDirector
- Jeffrey LeidenDirector
- Jason HaasExecutive Officer
- Nia TatsisDirector
- Ksenija PavleticDirector
- Shelley ChuDirector
- lan F. SmithDirector
- Jill CarrollDirector
- Offering amount
- $214M
- Amount sold
- $214M
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$117.2MraisedAug 2024 · 43 investors · BiotechnologyRule 506(b)
- Timothy WalbertDirector
- Charles M. BaumDirector
- Gary D. GlickExecutive Officer, Director
- Jill CarrollDirector
- Jeffrey LeidenDirector
- Ian SmithDirector
- Valerie OdegardDirector
- Lorence KimDirector
- Carl GordonDirector
- Offering amount
- $121.1M
- Amount sold
- $117.2M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$168MraisedOct 2022 · 34 investors · BiotechnologyRule 506(b)
- Valerie OdegardDirector
- Jill CarrollDirector
- Carl GordonDirector
- Jeffrey LeidenDirector
- Charles BaumDirector
- Gary D GlickExecutive Officer, Director
- Offering amount
- $174.9M
- Amount sold
- $168M
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$91.6MraisedOct 2021 · 63 investors · BiotechnologyRule 506(b)
- Carl GordonDirector
- Chuck BaumDirector
- Valerie OdegardDirector
- Gary D GlickExecutive Officer, Director
- Jill CarrollDirector
- Amount sold
- $91.6M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Odyssey Therapeutics.
In the news
Frequently asked questions
- What does Odyssey Therapeutics do?
- Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation. Its pipeline focuses on autoimmune and inflammatory diseases with large patient populations and unmet medical need.
- Who founded Odyssey Therapeutics?
- Odyssey Therapeutics was founded by Gary D Glick in 2021.
- Who are Odyssey Therapeutics's investors?
- Odyssey Therapeutics's investors include Activant Capital, Ascenta Capital, Balderton Capital, Catalio Capital Management, LP, Foresite Capital, Global BioAccess Fund, GreatPoint Ventures, Jeito Capital and 8 more.
- How much funding has Odyssey Therapeutics raised?
- Odyssey Therapeutics has disclosed $894.9M raised across 5 rounds.
- Where is Odyssey Therapeutics headquartered?
- Odyssey Therapeutics is headquartered in Cambridge, US.